ClinicalTrials.gg
CompletedNCT02020746Updated Aug 31, 2018

Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds

A Phase 2 interventional study of EscharEx and Gel Vehicle in Hard to Heal Wounds, Venous Leg Ulcers and Diabetic Lower Extremity Ulcers, sponsored by MediWound Ltd. Completed at 8 sites in Israel. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by MediWound Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The main objective of this study is to assess the safety and the efficacy of EscharEx in preparing the wound's bed in patients with hard to heal venous leg ulcers, diabetic lower extremity ulcers and traumatic/post operative wounds.

This study will be a multi-center, assessor blinded, randomized, controlled study intended to demonstrate superiority of EscharEx debriding treatment over the Gel Vehicle control treatment in patients with hard to heal wounds.

72 + 24 adults with >50% necrotic/slough/fibrin non-viable tissue on a hard to heal wound (venous leg ulcer, diabetic lower extremity ulcer or traumatic/ post operative wound) between 5 cm2 and 200 cm2 (surface area in stage 1) or 3 cm2 - 150 cm2 (in stage 2), will be enrolled into the study.

Patients will undergo a 1 week screening period (2 visits) which will include: record of demographics, medical history and concomitant medications, vital signs, physical examination, clinical laboratory tests, wound photography and assessments and questionnaires (wound status and quality of life). During this period wounds will be treated by standard treatment per the decision of the physician. During this screening period, subjects whose study wound size (surface area) decreases by more than 20 percent will be excluded. Following completion of the screening process, eligible patients will be randomized to either EscharEx or Gel vehicle debridement treatments. In stage 1 (72 patients): Treatment will be performed for up to 10 applications or until complete debridement is achieved, whichever occurs first. In stage 2 (24 patients): Treatment will be performed for up to 8 applications or until complete debridement is achieved, whichever occurs first. Following each application the wound will be washed, photographed and assessed for wound size, removal of nonviable tissue and change in granulation tissue (by digital planimetry software), wound status, and safety parameters. Subsequent to each debridement treatment the wound will be dressed with moist-to-moist saline gauze (except when successive 24h or 48h treatments are performed, in the second stage). Following completion of the debridement treatment period, patients will be treated according to standard procedures and evaluated (wound assessments) once a week until complete wound closure for up to 12 weeks from last application (up to 12 visits). Only during the first stage of the study, for patients who achieved wound closure, additional 3 monthly (3 visits) follow- up visits of wound closure recurrence will be conducted. Quality of life (QoL) will be evaluated at the last follow-up visit - 3 months post wound closure follow-up period. For patients who didn't achieve wound closure only the 3 months FU visit will be conducted. For patients enrolled at the second stage, if wound closure was achieved at the 12 weeks follow-up, additional visit will be performed 2 weeks later to confirm wound closure.

02

Conditions studied

  • Hard to Heal Wounds
  • Venous Leg Ulcers
  • Diabetic Lower Extremity Ulcers
  • Traumatic/ Post Operative Wounds

Browse trials for

03

In context

Leg Ulcer

174 studies on the registry are indexed under Leg Ulcer; 33 are open to participants now.

This study's enrollment of 111 is above the median of 52 across 136 interventional studies indexed under Leg Ulcer.

Browse Leg Ulcer studies →

Lead sponsor

MediWound Ltd is the lead sponsor of 15 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients, men or women, are between 18 and 90 years of age.
  • Patient with venous leg ulcer or diabetic (lower extremity) ulcer or traumatic/post operative wound (determined by medical history and physical examination)
  • Wound is not healing for at least 4 weeks
  • The necrotic/slough/fibrin non-viable tissue area is at least 50% of wound area (assessed by clinical evaluation)
  • Wound surface area is in the range of 5- 200 cm2 in the first stage and 3 - 150cm2 in the second stage.
  • Patient understands the nature of the procedure, able to adhere to the protocol regimen, and provides written prior to any study procedure
  • The Wound is classified as a wound involving full skin thickness but not penetrating to cavities or open joint spaces

Exclusion criteria

Exclusion Criteria

  • Evidence of active osteomyelitis of target organ,
  • Patients with more than one hard to heal wounds wounds which require debridement and with an area greater than or equal to 2cm2,
  • Presence of purulent discharge, deep-tissue abscess, cellulitis or tissue damage extending >2 cm around the wound's edge, gangrene or signs of systemic infection,
  • Wound size decreased by > 20% after 1 week of standard-of-care-only period (screening period),
  • Patients with pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by Silver sulfadiazine (SSD) pseudoeschar (e.g. pseudoeschar as a result of SSD treatment),
  • Ankle-Brachial Index (ABI) ≤ 0.7 or a significant decrease in the blood flow of the extremity as demonstrated by US doppler.
  • Wound has sinus tracts or tunnels extending under healthy tissue,
  • Patients undergoing renal or peritoneal dialysis,
  • Recent history (less than 4 weeks) of myocardial infarction (MI) or concurrent acute injury or disease that might compromise the patient's welfare,
  • Any condition that would preclude safe participation in the study: evidence of significant hematological (severe pre-existing coagulation disorder), cardiovascular, liver or neoplastic disease, or any other immediate life threatening condition,
  • Patient is currently receiving, or has received at any time within one month prior to enrollment, any medications or treatments known to affect the wound healing processes; these include: chronic systemic intake with topical skin changes (thin, fragile with multiple hematomas and previous laceration history, immuno-suppressive drugs, radiation therapy and chemotherapy.
  • History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain,
  • Pregnant women (positive pregnancy test) or nursing mothers,
  • Participation in another drug trial within 30 days prior to enrollment or anticipated participation while enrolled in the study,
  • Concurrent use of non-approved drugs or alcohol abuse.
  • Patients with poor nutritional status (albumin \< 2.5g/dl), poor diabetic control ( > 12%), anemia (\<8 g/dL), a leukocyte counts \< 4,000// μl or >15000/μl, abnormal liver function (, ALT>2 x ), renal failure (Cr > 3 mg/dl);
  • Mentally incapacitated adults who are incapable of giving legal consent (e.g. dementia, psychiatric patients, etc),
  • Patients with general skin disorders (Psoriasis, Panniculitis, ect) that might deteriorate as a result of local trauma.
  • Patients with skin disorders unrelated to the wound that are presented adjacent to the wound
  • Clinical suspicion of skin cancer associated with the wound (e.g, BCC, SCC), which was not ruled out by Patients with diagnosed Sepsis during screening phase,
  • Patients suffering from Idiopathic Pruritus.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    EscharEx

    Enzymatic debridement

    Drug: EscharEx

  • Placebo comparator
    Gel Vehicle

    Control arm

    Drug: Gel Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of complete debridement (non-viable tissue removal) at the end of the debridement period assessed by the blinded assessor by clinical evaluation.

    Time frame: up to 10 treatment days

Secondary outcomes

  1. Rate of complete wound closure

    Time frame: 12 weeks post debridement

07

Study locations

8 sites
  • Emek
    Afula, Israel
  • Rambam MC - Plastic surgery ward
    Haifa, Israel
  • Meir MC
    Kfar Saba, Israel
  • Galilee
    Nahariya, Israel
  • HaSharon hospital, Rabin MC
    Petah Tikva, Israel
  • Sheba MC
    Ramat Gan, Israel
  • Kaplan
    Rehovot, Israel
  • Assaf HaRofeh
    Zrifin, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Dec 2017, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2013
First posted
Dec 25, 2013
StartActual
Jul 24, 2014
Primary completionActual
Dec 5, 2017
CompletionActual
Jun 4, 2018
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02020746
Lead sponsor
MediWound Ltd
Responsible party
Sponsor
First posted
Dec 25, 2013
Start date
Jul 24, 2014
Primary completion
Dec 5, 2017
Completion
Jun 4, 2018
Last update
Aug 31, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem bromelain

Start the discussion